Highly Potent, Perfectly Packaged

PCI Pharma Services has invested in a best-in-class clinical to commercial scale potent packaging suite at its Tredegar, UK, site. The goal? To provide a truly integrated end-to-end service for clients – from the manufacturing of highly potent drug products to packaging.
Highly potent APIs (HPAPIs) are highly challenging, and not all CDMOs have the true capability to manufacture or package them. PCI Pharma Services has significant experience in the handling of highly potent products and has recently further invested in its Tredegar site in Wales, UK by adding a second contained manufacturing facility and a state-of-the-art potent packaging suite. In this roundtable, PCI experts run us through the project by discussing the attention to technical detail required to ensure that the required high standards and regulatory controls were not only met but also exceeded.
The Experts
- Rob Jones: Executive Director, Business Development, Manufacturing EMEA/APAC
- Adam Pugsley: Program Lead for CAPEX Projects
- Natashia Eales: Head of Technical and Regulatory Quality
- Shaun Engelhardt: CAPEX Programme Manager
- Ben Potter: Validation Manager
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Clinical Supply Leader? Subscribe today.